IP Library Granted Patent US 9,896,508
Granted Patent B2
US 9,896,508 · App. 15/169,211 · Granted Feb 20, 2018

Antibodies reactive with B7-H3 and uses thereof

Inventors: Leslie S. Johnson (Darnestown, MD); Ling Huang (Bethesda, MD); Paul A. Moore (North Potomac, MD); Deryk T. Loo (Belmont, CA); Francine Zhifen Chen (San Francisco, CA)
Assignee: MacroGenics, Inc.
C07K16/2827A61K39/39558A61K45/06A61K47/48561A61K47/48569C07K16/2809C07K16/30C07K16/3023C07K16/3046C07K16/3069G01N33/57484A61K2039/505C07K2317/24C07K2317/31C07K2317/33C07K2317/622C07K2317/626C07K2317/73C07K2317/76C07K2317/77C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,896,508
App. No.
15/169,211
Granted
Feb 20, 2018
Kind
B2
Abstract

The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Claims (16)

1. A nucleic acid molecule comprising a sequence encoding a polypeptide comprising:

(A) a light chain having the amino acid sequence of SEQ ID NO: 117; or

(B) a heavy chain having the amino acid sequence of SEQ ID NO: 119.

2. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the light chain having the amino acid sequence of SEQ ID NO: 117.

3. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the heavy chain having the amino acid sequence of SEQ ID NO: 119.

4. The nucleic acid molecule of claim 3 , wherein the encoded polypeptide further comprises the light chain having the amino acid sequence of SEQ ID NO: 117.

5. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule comprises the light chain sequence of SEQ ID NO: 118.

6. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule comprises the heavy chain sequence of SEQ ID NO: 120.

7. The nucleic acid molecule of claim 6 , wherein said nucleic acid molecule further comprises the light chain sequence of SEQ ID NO: 118.

8. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide is a single chain antibody, a monoclonal antibody, or a diabody.

9. A vector comprising the nucleic acid molecule of claim 1 .

10. The vector of claim 9 , which is an expression vector.

11. A host cell comprising the expression vector of claim 10 .

12. A method of producing a substantially purified immunoglobulin or an antigen-binding fragment thereof, comprising the steps of:

(A) growing a cell line transformed with the nucleic acid of claim 1 under conditions in which the immunoglobulin or antigen-binding fragment thereof is expressed; and

(B) harvesting the expressed immunoglobulin or antigen-binding fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2017
From: JOHNSON, LESLIE S.; HUANG, LING; MOORE, PAUL A.; LOO, DERYK T.; CHEN, FRANCINE Z.
To: MACROGENICS, INC.
Reel/Frame 043839/0532 →
Continuity (8)
Continuation 14331876 · Jul 15, 2014
Division 13463924 · May 4, 2012
Continuation In Part PCTUS2011026689 · Mar 1, 2011
Provisional Application 61482771 · May 5, 2011
Provisional Application 61311057 · Mar 5, 2010
Provisional Application 61310695 · Mar 4, 2010
Provisional Application 61310692 · Mar 4, 2010
Related Publication 20160264672A1 · Sep 15, 2016